2 Risky Growth Stocks That Could Make You Filthy Rich

Growth stocks, on balance, have fallen out of favor in recent months. Political gridlock in Washington, D.C., historically high inflation rates, and concerns about an interest rate increase have dampened investors' appetite for risk. This negative sentiment, though, doesn't mean there aren't growth stocks worth buying right now. In the hard-hit area of biotech, for instance, a handful of hidden gems might be poised for jaw-dropping levels of growth in 2022 and beyond.

Which unloved biotech stocks should risk-tolerant investors have on their radar right now? Leap Therapeutics (NASDAQ: LPTX) and Pieris Pharmaceuticals (NASDAQ: PIRS) could both be gearing up for explosive moves to the upside later this year. While these two biotech stocks are indeed risky, their notable upside potential ought to appeal to aggressive investors on the hunt for unusual growth opportunities. Here's a brief overview on the pros and cons of each stock.

Image source: Getty Images.

Source Fool.com